Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease

Expert Opinion on Investigational Drugs

Volumn 24, Issue 5, 2015, Pages 603-610

  Rysz, Jacek ^a   Gluba Brzózka, Anna ^a   Mikhailidis, Dimitri P ^b   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Animal models; Fibroblast growth factor 19; Metabolic syndrome; Treatment

Indexed keywords

CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 19; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; INITIATION FACTOR 4B; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN TYROSINE PHOSPHATASE SHP; TRIACYLGLYCEROL; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; FAT CONTENT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; HUMAN; LIPOGENESIS; LIPOLYSIS; METABOLIC DISORDER; NONHUMAN; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; METABOLIC DISEASES; METABOLIC SYNDROME X; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; METABOLIC DISEASES; METABOLIC SYNDROME X; MICE; MOLECULAR TARGETED THERAPY;

EID: 84927645989     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1006357     Document Type: Review

References (62)

1. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012;12:56
2. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20(11):563-9
3. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16(2):139-49
4. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004;306(5701):1506-7
5. Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Molecular Metabolism 2014;3(3):221-9
6. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009;9(6):805-10
7. Adams AC, Coskun T, Rovira AR, et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 2012;7(5):e38438
8. Cicione C, Degirolamo C, Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 2012;56(6):2404-11
9. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8(3):235-53
10. Nishimura T, Utsunomiya Y, Hoshikawa M, et al. Structure and expression of a novel human FGF, FGF- 19, expressed in the fetal brain. Biochim Biophys Acta 1999;1444(1):148-51
11. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11(10):729-35
12. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1a pathway. Cell Metab 2011;13(6):729-38
13. Lundasen T, Galman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006;260(6):530-6
14. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factordependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17(13):1581-91
15. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7 alpha-hydroxylase gene expression. Hepatology 2009;49(1):297-305
16. Marcelin G, Jo YH, Li X, et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab 2013;3(1):19-28
17. Barutcuoglu B, Basol G, Cakir Y, et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011;41(4):390-6
18. Mráz M, Lacinová Z, Kaválková P, et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, verylow calorie diet and PPAR-a agonist treatment. Physiol Res 2011;60(4):627-36
19. Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009;7(11):1189-94
20. Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2011;17(6):1322-7
21. Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298(3):G440-5
22. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145(6):2594-603
23. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115(6):1627-35
24. Wöhrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF23 signaling and regulating FGF23 expression in bone. J Bone Miner Res 2011;26(10):2486-97
25. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012;26(4):312-24
26. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulinindependent activator of hepatic protein and glycogen synthesis. Science 2011;331(6024):1621-4
27. Wu X, Ge H, Baribault H, et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res 2013;54(2):325-32
28. Wu X, Ge H, Lemon B, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA 2009;106(34):14379-84
29. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143(5):1741-7
30. Stejskal D, Karpisek M, Hanulova Z, et al. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 2008;68(6):501-7
31. Fang Q, Li H, Song Q, et al. Serum fibroblast growth factor 19 levels are decreased in chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care 2013;36(9):2810-14
32. Ryan KK, Kohli R, Gutierrez-Aguilar R, et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 2013;154(1):9-15
33. Ciofi P. The arcuate nucleus as a circumventricular organ in the mouse. Neurosci Lett 2010;487(2):187-90
34. Warne JP, Xu AW. Metabolic transceivers: in tune with the central melanocortin system. Trends Endocrinol Metab 2013;24(2):68-75
35. Qureshi HA, Pearl JA, Anderson KA, et al. Fibroblast growth factor 19 activates the unfolded protein response and mitogen-activated protein kinase phosphorylation in H-69 cholangiocyte cells. J Liver 2014;3(3):158
36. Kim I, Ahn SH, Inagaki T, et al. Differential regulation of bile acid homeostasis by the farnesoid x receptor in liver and intestine. J Lipid Res 2007;48(12):2664-72
37. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of bKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282(37):26687-95
38. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by bKlotho. J Cell Physiol 2008;215(1):1-7
39. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor- 19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009;284(15):10023-33
40. Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol 2011;76:130-44
41. Shin DJ, Osborne TF. FGF15/ FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 2009;284(17):11110-20
42. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2(4):217-25
43. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000;275(20):15482-9
44. Zhang J, Li HT, Fang QC, et al. Role of fibroblast growth factor 19 in maintaining nutrient homeostasis and disease. Biomed Environ Sci 2014;27(5):319-24
45. Ge H, Baribault H, Vonderfecht S, et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One 2012;7(3):e33603
46. Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010;285(8):5165-70
47. Obici S, Feng Z, Tan J, et al. Central melanocortin receptors regulate insulin action. J Clin Invest 2001;108(7):1079-85
48. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27(1):85-97
49. Wu AL, Coulter S, Liddle C, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 2011;6(3):e17868
50. Ge H, Zhang J, Gong Y, et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J Biol Chem 2014;289(44):30470-80
51. Wu X, Ge H, Lemon B, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci USA 2010;107(32):14158-63
52. Huang X, Yang C, Luo Y, et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007;56(10):2501-10
53. Morton GJ, Matsen ME, Bracy DP, et al. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 2013;123(11):4799-808
54. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160(6):2295-307
55. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012;12:56
56. Patman G. Liver: a variant of FGF19 protects the liver from cholestatic injury without inducing cancer. Nat Rev Gastroenterol Hepatol 2014;11(10):579
57. Rizzo M, Nikolic D, Banach M, et al. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des 2014;20(31):4953-60
58. Gao X, Wang G, Zhang W, et al. Expression of pulmonary aquaporin 1 is dramatically upregulated in mice with pulmonary fibrosis induced by bleomycin. Arch Med Sci 2013;9(5):916-21
59. Gluba A, Banach M, Mikhailidis DP, et al. Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In Vivo 2009;23(5):797-812
60. Gundogan K, Bayram F, Gedik V, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci 2013;9(2):243-53
61. Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol 2014;46(5):947-61
62. Zhu Y, Ding X, Fang C, et al. Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure. Mol Pharmacol 2014;85(1):139-47